HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors

HRYZ Biotech

Status and phase

Enrolling

Phase 1

Conditions

Hepatic Cell Carcinoma

Treatments

Biological: AFP Specific T Cell Receptor T Cells

Study type

Interventional

Funder types

Industry

Identifiers

NCT06515314

H-T02-C1001

Details and patient eligibility

About

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to prior systematic treatments.

Full description

This study plans to enroll 12-24 patients to assess the safety of HRYZ-T102. Subjects who meet the eligibility criteria will receive a single dose of HRYZ-T102 injection .The patient will be followed up 24 months.

Enrollment

12 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The patient must be willing to sign the informed consent form.
Age ≥18 years and ≤75 years.
HLA-A 02:03 allele positive
Histologically-confirmed AFP positive hepatocellular carcinoma (HCC) or other solid tumor, No benefits from curative surgery or other local therapies are expected ,at least one prior line of systematic treatment at screening, judged by investigators.
Fresh samples or formalin-fixed paraffin-embedded (FFPE) samples, immunohistochemistry (IHC)-stained AFP positive or serum AFP ≥400ng/ml.
Barcelona Clinic Liver Cancer (BCLC) stage C or B and Child-Pugh ≤7
ECOG performance status ≤1.
Estimated life expectancy ≥4 months.
Patients must have at least one measurable lesion defined by RECIST 1.1.
Patients with any organ dysfunction as defined below:

Leukocytes≥3.0 x 10^9/L; blood platelets ≥75 x 10^9/L; hemoglobin≥85g/L; Absolute lymphocyte count≥0.8 x 10^9/L Serum albumin ≥ 30g/L; total bilirubin≤3×ULN; ALT/AST≤3×ULN ; Creatinine clearance ≥50mL/min; or serum creatinine ≤1.5×ULN; INR≤1.5×ULN; APTT≤1.5×ULN; LVEF≥50%; SpO2≥92%.
Subjects with potential fertility must agree to use effective contraceptive methods during the whole trials period and at least 1 year after receiving HRYZ-T102 cell transfusion treatment. HCG test for female with potential fertility must be negative within 7 days before apheresis.

Exclusion criteria

Toxicity of previous treatment has not been mitigated or ≤ Grade 1 at screening.
Another primary malignancy within 5 years (with some exceptions for completely-resected early-stage tumors)
With severe cardiovascular disease or presence of clinically-relevant central nervous system (CNS) disorders in six months before screening.
Systematic autoimmune disorders requiring long-term systematic immunosuppression
Have a history of hypersensitivity to cyclophosphamide or fludarabine, and it is known that any ingredient used in the treatment of this study will produce allergic reactions.
Current presence of or previously with hepatic encephalopathy
Organ transplanters and allogeneic cell transplanters.
Have a history of gastrointestinal bleeding or a definite tendency to gastrointestinal bleeding within 3 months before screening
Hereditary or acquired bleeding (e.g. coagulation dysfunction) or a tendency to clot
Subject has active infection or unexplained fever during screening and prior to cell transfusion
Have central nervous system metastasis with symptoms
Known HIV or syphilis infection, and/or active hepatitis C virus infection.
HBV infect subjects with HBV-DNA≥2000IU/ml
Pregnant or lactating female, or those whose HCG test is positive before enrollment.
Known uncontrolled diabetes, pulmonary fibrosis, interstitial lung disease, acute lung disease or liver failure